Harvard Bioscience Appoints Yong Sun as VP Strategic

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Harvard Bioscience Appoints Yong Sun as VP Strategic Marketing and Business Development

Nearly 20 Years Marketing Experience to Bolster Company's Future Expansion Into Asia and Emerging Markets

Second New Global Position Adds Depth to Company's International Growth Initiatives

HOLLISTON, Mass., Oct. 28, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO ), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, has hired Yong Sun, a veteran global marketing and sales leader in the life sciences and medical device industries, as Harvard Bioscience's Vice President Strategic Marketing and Business Development, a newly created position, effective October 28.

Jeffrey A. Duchemin, Chief Executive Officer of Harvard Bioscience, commented, "In our quest to advance Harvard Bioscience's status as a company with a truly international footprint, it is imperative that our team include informed strategic thinkers with a global perspective. It is for this reason that we have created the new position of Vice President Strategic Marketing and Business Development. I am honored that Yong Sun, a native of Beijing with more than 25 years experience working for leading U.S. companies, has accepted this role. I have worked with Yong in the past and can say with the highest level of confidence, that he is the right person for this new position. His impressive career experience in marketing and sales in the life science sector, especially his experience growing businesses in Asia, along with his distinguished academic background, make him especially qualified to guide us in our move into emerging markets."

In his new position, Mr. Sun will be working closely with HBIO's recently appointed VP of Global Sales, Yoav Sibony, to increase the Company's international footprint.

Mr. Sun, age 49, holds an M.B.A. from the MIT Sloan School of Management. Prior to joining Harvard Bioscience, he served as Vice President of Global Marketing and Americas Sales at Beaver-Visitec International, a company combining former ophthalmic business units from Becton, Dickinson & Company (BD) and Medtronic; in this role he led global marketing to develop and implement strategic marketing plans in target surgical markets. Prior to this, he served in progressive positions at BD, including Director of Global Marketing & U.S. Sales. Earlier, he served as Marketing Manager, Global Life Sciences Market & Greater China Region at Eli Lilly & Company's eLilly Unit (now InnoCentive, Inc.). Among other achievements, he established InnoCentive's R&D network in Greater China, launched their Chinese website, and planned and implemented an integrated marketing campaign in the China region. Mr. Sun earned a master of science degree in environmental science & engineering from Northeastern University and a bachelor of science degree in biochemistry from Peking University.

Yong Sun stated, "Harvard Bioscience's goal of taking full advantage of emerging markets will require a novel business strategy that incorporates a profound knowledge of the life science business overseas. With effective global and marketing development programs in place, it is my belief that the Company will cement its reputation as an international leader in its field. I look forward to serving as Vice President Strategic Marketing and Business Development and working with Harvard Bioscience's management as the Company moves ahead."

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. Our products are sold to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit our website at www.harvardbioscience.com .

The Harvard Bioscience, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the future expansion of Harvard Bioscience into Asia or emerging markets, and appointment of Mr. Yong Sun as Harvard Bioscience's Vice President Strategic Marketing and Business Development. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release, including that Harvard Bioscience may be unsuccessful with respect to any future expansion it may seek to undertake into Asia or emerging markets. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.

Jeffrey A. Duchemin Chief Executive Officer (508) 893-8999 Investor Relations: Dian Griesel Inc. Cheryl Schneider (212) 825-3210 Public Relations: Dian Griesel Inc. Susan Forman or Laura Radocaj (212) 825-3210

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

China Pharma Unveils New Share Offering to Fuel Growth

Updated Category News Views 114

China Pharma Unveils New Share Offering China Pharma Holdings, Inc. (NYSE American: CPHI) has recently filed a prospectus supplement that enables the company to connect with investors through an innovative equity offering. This announcement signifies an important step in the company’s journey, allowing it to sell shares valued at up to $600,000. This move not only...

Continue Reading
Unum Group Delivers Stellar Third Quarter 2024 Financial Results

Updated Category News Views 186

Unum Group Financial Highlights for Q3 2024 Unum Group (NYSE: UNM) has reported impressive net income of $645.7 million, or $3.46 per diluted common share, for the third quarter of 2024. This marks a significant increase compared to net income of $202.0 million, or $1.02 per diluted common share, recorded in the same quarter of the previous year. The company’s...

Continue Reading
Latest Financial Overview of Perimeter Solutions Inc for Q2 2025

Updated Category News Views 222

Perimeter Solutions Financial Performance Report In the latest financial reports, Perimeter Solutions, Inc. (PRM) has showcased significant progress in its fiscal performance for the second quarter. The reported figures paint a comprehensive picture of the company's financial health and operational success. Revenue Growth During the second quarter of 2025, Perimeter...

Continue Reading
Everyday Decisions That Quietly Shape Your Financial Future

Updated Category Personal Finance Views 1451

Ever wondered how your daily choices impact your financial future? Everyday decisions that quietly shape your financial future can significantly influence your financial stability. Small habits like tracking expenses, choosing the right credit card, and consistent saving set the stage for long-term security. Discover how these simple actions can transform your financial...

Continue Reading
Core Bank Partners with Kobalt Labs to Enhance Compliance

Updated Category News Views 130

Core Bank Enhances Risk and Compliance with Kobalt Labs Core Bank is undertaking a significant transformation in its risk and technology framework, with a strong focus on artificial intelligence (AI). This strategic shift aims to bolster the institution's operational foundation, ultimately leading to enhanced service for the community, customers, and the broader business...

Continue Reading